Therapeutic Administration of an SMYD2‐Specific Inhibitor Attenuates Renal Injury in Mice With Cisplatin‐Induced CKD and Suppresses the Upregulation of Extracellular Matrix (ECM) Protein Expression in Kidney Tissues. The gene discussed is SMYD2; the disease is chronic kidney disease.